HHS draft policy does not intend to act against compounding six peptides that meet strict conditions

Cette fiche est affichée en anglais jusqu’à la mise à jour de sa traduction.

The US Department of Health and Human Services announced a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 while the FDA's 503A bulk substances list is developed through rulemaking, but only when every condition in the policy is met. Those conditions include using only the peptide form and route of administration the policy lists, one active ingredient per product, a patient-specific prescription, a raw ingredient made by an FDA-registered manufacturer following good manufacturing practice with a valid certificate of analysis (lab test report), and reporting serious adverse events to the FDA. The notice, published in the Federal Register on 30 October with written comments accepted for two weeks, says the policy is not binding and may be revisited if a safety signal or product quality issue arises. It does not approve these peptides or add them to the list, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.

Sources

  1. 01Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(ouvre la source dans un nouvel onglet) Federal Register
  2. 02Draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(ouvre la source dans un nouvel onglet) US Department of Health and Human Services
  3. 03HHS to allow compounders to make 6 unapproved peptides(ouvre la source dans un nouvel onglet) BioPharma Dive
  4. 04HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending(ouvre la source dans un nouvel onglet) Arnold & Porter

Peptides concernés

  1. Non autoriséBPC-157Pentadécapeptide gastrique synthétique (produit chimique de recherche)15 Interdit par la WADA
  2. Non autoriséEpitalonTétrapeptide pinéal synthétique (candidat géroprotecteur)4 Interdit par la WADA
  3. Non autoriséKPVTripeptide dérivé de l’alpha-MSH (produit chimique de recherche)3 Interdit par la WADA
  4. Non autoriséMOTS-cPeptide d’origine mitochondriale (peptide de recherche)16 Interdit par la WADA
  5. Autorisé ailleursSemaxAnalogue du fragment ACTH(4-10) (neuropeptide dérivé des mélanocortines)7
  6. Non autoriséTB-500Fragment de la thymosine bêta-4 (produit chimique de recherche)7 Interdit par la WADA